New drug in MS

A second-generation anti-CD40L monoclonal antibody has shown remarkable efficacy in reducing multiple sclerosis (MS) disease activity, according to new trial data. This treatment nearly eliminated new brain lesions on MRI scans at 48 weeks for patients receiving the highest dose, without increasing the risk of infections or thrombotic events.

In a phase 2 trial, 96% of patients on the 1200 mg dose were free of new gadolinium-positive (Gd+ T1) lesions at 48 weeks, with low annual relapse rates. This study, presented at the CMSC 2024 Annual Meeting, also highlighted the drug's stability in lymphocyte counts and immunoglobulin levels, suggesting a safer profile compared to first-generation treatments.

The CD40-CD40L pathway, critical in MS inflammation, has been targeted for years, but earlier drugs faced challenges due to thromboembolic risks. This newer antibody avoids such issues by not interacting with platelets. Ongoing phase 3 trials aim to confirm these promising results, potentially offering a groundbreaking advancement in MS treatment.